FDA

Food and Drug Administration logo

FDA Keeps Driving Up Future Cost of Inhalable Insulin

MannKind Corp. (NASDAQ: MNKD) is suffering another setback from the U.S. Food & Drug Administration. While the FDA has been far from a friend to MannKind over the past few ...
Read Full Story »
76764023

Can MannKind Shares Double Again on FDA Approval? (Final)

MannKind Corp. (NASDAQ: MNKD) has a serious victory within its grasp. The company has struggled to get its Afrezza inhalable insulin to market for years, and that dream now seems ...
Read Full Story »
153576724

Vindication for MannKind With FDA Panel Backing

MannKind Corp. (NASDAQ: MNKD)had been trading as though the stock was bracing for an U.S. Food and Drug Administration (FDA) panel decision recommending against the approval of its inhalable insulin ...
Read Full Story »
Pills

Zogenix CEO Goes on the Offensive

Zogenix Inc. (NASDAQ: ZGNX) has traded like a company that is about to implode. Its highly controversial Zohydro has been getting inquiries into how it was approved for marketing despite ...
Read Full Story »
Pills

Back to Normalcy at Geron

Geron Corp. (NASDAQ: GERN) is getting a reality check on Wednesday. After a recovery from years of disappointment, this is starting to feel again like the Geron that everyone knew ...
Read Full Story »
DNA

Dendreon Finds New, Long Overdue Lifeblood

Shares of Dendreon Corp. (NASDAQ: DNDN) moved higher Monday after the biotech company said it will start to market Provenge, its prostate-cancer drug, in Europe this year. The announcement came ...
Read Full Story »
knees

Anika Arthritis Treatment Approval Brings All-Time Highs, Maybe More to Come

Shares of biotechnology company Anika Therapeutics Inc. (NASDAQ: ANIK) soared to an all-time high Wednesday after the company said the U.S. Food and Drug Administration (FDA) had approved its drug ...
Read Full Story »
biotech

Chelsea Moving on to the Revenue Stage of Its Cycle

Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) is finding a serious victory from its hypotension drug. Shares hit a 52-week high -- make that a three-year high -- after the company ...
Read Full Story »
76764023

Volatility and Options in MannKind Shaking Speculators Out

MannKind Corp. (NASDAQ: MNKD) is a stock that has been on a wild ride for many years. The company's inhalable insulin has been held up from being approved for years ...
Read Full Story »
Stock Split Image

The Questionable Dendreon Buyout Incentive

Dendreon Corp. (NASDAQ: DNDN) is by almost all measurements nothing short of a total failure of a biotech or biohealth stock. Despite having a solid prostate cancer treatment in Provenge, ...
Read Full Story »
biotech

pSivida, Alimera and Ariad Join Bio-Implosion Watch

Biotech and emerging health care technology companies both fit into a high-stake poker match on Wall Street. Investors can earn exponential rewards if they are right, or they can lose ...
Read Full Story »
145922793

Is Inhalable Insulin Assured To Be Approved By The FDA?

If you have followed the diabetes drug market for very long, chances are high that you have run across the possibility of an inhalable form of insulin ultimately being approved ...
Read Full Story »
Stock Split Image

Coronado Implodes over Crohn’s Failure, Future Now Uncertain

Investing in biotech and emerging pharmaceutical stocks comes with a huge risk and reward profile for investors. Some wins are exponential, yet some losses are losses of the entire investment. ...
Read Full Story »
Food and Drug Administration logo

FDA Hold on Ariad Kills $2 Billion in Value (Updated)

Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) is getting crushed on Wednesday due to a clinical hold placed by the U.S. Food & Drug Administration. The company confirmed that the FDA has ...
Read Full Story »
Haiti

When Data Conflicts: Is the Malaria Vaccine Data Good or Bad?

A malaria vaccine is supposed to be a good thing. Right? Unfortunately that all depends. GlaxoSmithKline PLC (NYSE: GSK) currently plans to seek marketing approval for the first malaria vaccine ...
Read Full Story »